You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk

https://doi.org/10.1136/ebm.11.6.177

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–41.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In postmenopausal women at increased risk, what is the comparative efficacy and safety of raloxifene and tamoxifen for preventing invasive breast cancer?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Oncology ★★★★★★☆ Endocrine ★★★★★☆☆

    METHODS

    Embedded ImageDesign:

    randomised controlled trial.

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (clinicians, participants, and outcome assessors).*

    Embedded ImageFollow up period:

    mean 3.9 years.

    Embedded ImageSetting:

    nearly 200 clinical centres in North America.

    Embedded ImageParticipants:

    19 747 postmenopausal women ⩾35 years of age (mean age 59 y) whose 5 year predicted risk of breast cancer was ⩾1.66% (mean 4.03%) based on the Gail model. Exclusion criteria included recent hormone therapy use; stroke or venous thromboembolism (VTE) history; cancer in the previous 5 years; and uncontrolled atrial fibrillation, diabetes, or hypertension.

    Embedded ImageIntervention:

    raloxifene, 60 mg/day (n = 9875), or tamoxifen, …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr V G Vogel, University of Pittsburgh, Pittsburgh, PA, USA. vvogel{at}magee.edu

    • Sources of funding: National Cancer Institute; AstraZeneca; Eli Lilly.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 191-191 Published Online First: 30 Nov 2006. doi: 10.1136/ebm.11.6.191-a